Modern business intelligence demands speed, and utilizing AI tools for Excel is the ultimate way to hyper-charge your data workflows this year.

Spread the love“`html Airtable has rapidly gained popularity as a versatile database tool that combines the functionality of a spreadsheet with the power of a database. One of its standout features is ...

The growing complexity of connected cars and their network of potentially vulnerable components makes modern vehicles a lucrative target for hackers. Sensitive driver information remains at risk, even ...

OpenAI is bringing ChatGPT directly into Microsoft Excel and Google Sheets, letting users build, edit, and understand spreadsheets. It can create sheets from scratch, clean messy data, fix formulas, ...

As global temperatures rise, data centers for artificial intelligence are creating “heat islands” that could have significant impacts on communities and their surrounding environments in the years to ...

Geofence searches allow law enforcement to find suspects and witnesses by sweeping up location data from cellphone users near crime scenes. By Ann E. Marimow Reporting from Washington When the Call ...

Across southeastern Wyoming, something much larger than a single wind project is taking shape. From Rawlins to Cheyenne and north through Horse Creek toward Chugwater, industrial wind development is ...

Amazon's AI boom is creating a new kind of mess: a growing bloat of internal tools and duplicated data. Some teams are rapidly building their own AI-powered applications to automate workflows and ...

Power demand by data centers is rapidly rising. Data center developers need to secure power supplies in advance to avoid delays. Oracle is expanding its partnership with Bloom Energy to secure more of ...

The data centers at the heart of the AI boom are producing so much heat that they’re spiking land temperatures for miles around them by up to 16 degrees Fahrenheit, new research suggests. The effect ...

Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later ...